AD16 / SCCIP, Guangzhou Institutes of Biomedicine and Health - LARVOL DELTA

Safety, tolerability, pharmacokinetics and effects of diet on AD16, a novel neuroinflammatory inhibitor for Alzheimer's disease: a randomized phase 1 study. (PubMed, BMC Med) - P1 | "The present study exhibited favorable safety, tolerability, and PK profile of AD16, supporting its further research as a potential drug treatment for AD."

Journal • P1 data • PK/PD data • Alzheimer's Disease • CNS Disorders • Inflammation